World Vaccine Congress Washington, April 7-9 2015

Download eBook: Discussion topics from Pandemic Influenza, 2nd Edition

Pandemic influenza is a re-emerging disease with serious public health consequences. The H1N1 pandemic in 2009-10 and the continuing threat to humans from avian influenza H5N1 and H5N8 have underlined this threat. Particularly in an increasingly globalised society, it is essential that we have preparedness plans in please at a local, national and international level. Download this eBook to: Gain …

Advaxis Secures $23 Million Financing

Last week, Advaxis, Inc. (a clinical-stage biotechnology company developing cancer immunotherapies on its proprietary Lm-LLO platform technology), announced that a combined $23 million of purchase agreements was raised, worth approximately 3.1 million shares, at a price of $7.50 per share from several institutional investors. The investors include Adage Capital Management, L.P. Broadfin Capital LLC, Sectoral Asset Management, Cormorant Asset Management and …

Inovio Presents Phase II Clinical Efficacy Data at the 15th World Vaccine Congress

With the 15th World Vaccine Congress on 13 – 15 October in Brussels is just next month I conducted an interview to one of our key speakers, Dr. Niranjan Y. Sardesai (COO, Inovio Pharmaceuticals, Inc.) to give you further insight into his new exciting clinical data and current challenges in developing cancer DNA vaccines.  Dr. Sardesai has broad development and …

Bettina Klug, PEI: The Future of Genetic Modification in Vaccine Development

The vaccine industry is in a time where there is a lot to be excited about around new developments. However, these new approaches to vaccine development bring significant challenges in terms of bringing them to market. Earlier this year the VaccineNation team were able to sit down with Dr Bettina Klug, Scientific Administrator at the Paul-Ehrlich-Institut to understand her thought …

The Animal Medicine and Veterinary Vaccines Sector – a $22 billion market

As highlighted by Zoetis , the largest global animal healthcare company and latest exhibitor partner to the Vaccine Congress Washington 2015, the animal medicines and veterinary vaccines sector is estimated to represent a global market of $22 billion within the approximate $92 – 102 billion animal health industry.   Additionally between 2011 and 2016, the animal medicines and vaccines sector is …

Top 4 Challenges for Vaccine Manufacturers

Recently we undertook the research for the 15th annual World Vaccine Congress, and so asked what the biggest challenges are for each segment of the market. When we spoke to vaccine manufacturers, these came up as the 4 biggest issues:   1)      Adjuvants Adjuvants are often lauded as the way forward to make vaccines more effective, but given how new …

Vaccine Asia

Vaccine Asia Live: Overcoming the Challenges of Vaccine Trials to Address the Growing Demand in Asia

Seeing the great importance of vaccine development in Asia due to its great demand, it is pertinent that any challenges in vaccine development be addressed, especially in vaccine clinical trials. To help address these challenges, Dr Teoh Yee Leong, CEO of Singapore Clinical Research Institute(SCRI) , spoke about what these challenges were and advice on how to overcome them. Singapore …

Vaccine Asia Live: NIAID’s Effort on Dengue Vaccine R&D

Addressing Asia’s needs for vaccines in dengue, Dr Zou Lanling, Bacteriology Program Officer & Chief of Translational Sciences Section of National Institutes of Health USA, shared the efforts put into dengue vaccine R&D by National Institute of Allergy and Infectious Diseases(NIAID). NIAID conducts and supports research to develop vaccines, therapeutics and diagnostics to help understand, treat, and prevent infectious, immunologic, …